1 / 19

Addressing emerging diseases on the grid

Addressing emerging diseases on the grid. Vincent Breton, CNRS-IN2P3, LPC Clermont-Ferrand Credits: Ying-Ta Wu (Academia Sinica, Taïwan) Doman Kim (Chonnam National University, Korea). « Communication is the key to controlling communicable diseases »

jhoffer
Download Presentation

Addressing emerging diseases on the grid

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Addressing emerging diseases on the grid Vincent Breton, CNRS-IN2P3, LPC Clermont-Ferrand Credits: Ying-Ta Wu (Academia Sinica, Taïwan) Doman Kim (Chonnam National University, Korea) « Communication is the key to controlling communicable diseases » Anita Barry, director of Communicable Disease Control, Boston Public Health Commission V. Breton, IFI, 081107

  2. Emerging diseases, a growing burdeon on public health • Several new diseases have emerged in the last decades (HIV/AIDS, SRAS, Bird Flu) • They constitute a growing threat to public health due to world wide exchanges and circulation of persons Bird flu status on January 15th 2008: - 86 human cases in 2007, 58 deaths - 1 lethal case in 2008 - 30 countries infected by H5N1 in 2007 V. Breton , FCPPL, 150108

  3. Addressing emerging diseases International collaboration is required for: Prevention (common health policies) Epidemiological watch Early detection and warning Search for new drugs Search for vaccines V. Breton , FCPPL, 150108

  4. Searching for new drugs Drug development is a long (10-12 years) and expensive (~800 MDollars) process In silico drug discovery opens new perspectives to speed it up and reduce its cost V. Breton , FCPPL, 150108

  5. Screening • Biologists identify a protein involved in the metabolism of the virus: the target • The goal is to find molecules to prevent the protein from playing its role in the virus life cycle: the hits • Hits dock in the active site of the protein • in silico vs in vitro screening • In silico: computational evaluation of binding energy • In vitro: optical measurement of chemical reaction constant V. Breton , FCPPL, 150108

  6. Molecular docking Millions Molecular dynamics 5000 AMBER Re-ranking MMPBSA-GBSA Ligand CHIMERA Amber 4 H bonds Complex visualization 180 Ligand Catalytic aspartic residues Catalytic aspartic residues Ligand 2 Hydrogen Bonds Catalytic aspartic residues In vitro tests 30 WET LABORATORY Virtual screening workflow FLEXX AUTODOCK Credit: D. Kim V. Breton , FCPPL, 150108

  7. NA HA NA is involved in the replication of virions First large scale grid deployment on avian flu • Goal n°1: find new drug-like molecules with inhibition activity on neuraminidase N1, target of the existing drugs (Tamiflu) against avian flu • Method: large scale docking of 300.000 selected compounds against a neuraminidase N1 structure published in PDB Credit: Y-T Wu V. Breton , FCPPL, 150108

  8. : Predicted mutation site by structure overlay and sequence alignment : Reported mutation site Anticipate the mutations • Emerging diseases are characterized by rapidly mutating viruses • Mutations can be predicted • Structures can be modified • Goal n°2: quantify the impact of 8 mutations on known drugs and find new hits on mutated targets V. Breton , FCPPL, 150108

  9. Compounds: ZINC: 4.3M Chembridge: 500 000 Molecular docking (FlexX, Autodock) ~1 to 15 minutes Data challenge on EGEE ~ 2 to 30 days on ~5000 computers Targets: PDB: 3D structures Cheap and fast! Hits screening using assays performed on living cells Leads Selection of the best hits Clinical testing Drug Grid-enabled virtual docking Millions of potential drugs to test against interesting proteins! High Throughput Screening 1-10$/compound, several hours V. Breton , FCPPL, 150108

  10. Data challenges on avian flu and malaria *: use of DIANE/GANGA and WISDOM production environments V. Breton , FCPPL, 150108

  11. Point mutations do impact inhibitory effectiveness T01:E119A T05:R293K Variation of docking score on wild type (T06) and mutated targets potential hits T01 E119A V. Breton , FCPPL, 150108

  12. In vitro tests at Chonnam National University 4-Methylumbeliferyl-N-acetyl-a-D-neuramininic acid ammonium salt [4MU-NANA]; Substrate First screening (200 nmol) Recombinant Neuraminidase Spectrofluorometric detector RF-551 362 nm excitation and 448 nm emission wavelengths Second screening (2 nmol) Red Kinetic study Inhibition Blue

  13. Results on 308 compounds tested in vitro 4MU-NANA : 20 mM/RM Neuraminidase : 10 mU/reaction Measure at excitation 362 nm and emission at 448 nm On UV

  14. The second data challenge • N1 targets • PDB structures: open and close conformations (2HU0, 2HU4) • wild type + 3 mutations (H274, R293, E119) • prepared by Italian and Taiwanese teams (Dr. Luciano Milanesi and Dr. Ying-Ta Wu) • Compounds • 300,000 lab-ready compounds from Dr. Ying-Ta Wu (Academia SInica, Taiwan) • 200,000 compounds from Dr. Kun-Qian Yu (Shanghaï Institute of Materia Medica, CAS, China) V. Breton , FCPPL, 150108

  15. Grids for early warning network • Critical importance of global early warning and rapid response • SARS • Identified keys to set up successful warning network • increased political will • resources for reporting • improved coordination and sharing of information • raising clinicians' awareness, • additional research to develop more rigorous triggers for action. V. Breton , FCPPL, 150108

  16. Public Public Public Public Public Public Private Private Private Private Private Private A data grid to monitor avian flu • Each database to collect at a national level • Genomics data on virus and targets • Epidemiological data: information on human and bird cases • Geographical data: maps of outbreaks • Chemical data: focussed compound libraries Collaboration started with IHEP and CNIC within FCPPL: - Definition of data model - Implementation using AMGA metadata catalogue V. Breton , FCPPL, 150108

  17. SCAI Fraunhofer: Knowledge extraction, Chemoinformatics LPC Clermont-Ferrand: Biomedical grid CEA, Acamba project: Biological targets, Chemogenomics Chonnam nat. univ.: In vitro testing Univ. Modena: Biological targets, Molecular Dynamics KISTI: Grid technology HealthGrid: Biomedical grid, Dissemination ITB CNR: Bioinformatics, Molecular modelling Academica Sinica: Grid user interface Biological targets In vitro testing Univ. Los Andes: Biological targets, Malaria biology Univ. Pretoria / CSIR: Bioinformatics, Malaria biology Mahidol Univ.: Biochemistry, in vitro testing Conclusion • The grid provides the centuries of CPU cycles required for in silico drug discovery • 20% of the compounds selected in silico show better inhibition activity on H5N1 than Tamiflu during in vitro tests • The grid offers a collaborative environment for the sharing of data in the research community on emerging diseases V. Breton , FCPPL, 150108

  18. Perspectives • Avian flu • In vitro tests of the compounds selected in silico for mutated targets • Second data challenge under way to be analyzed in Taïwan • Set-up of data repositories with grid data management services • Other diseases • Malaria • already 2 compounds identified with strong inhibition activity on the parasite -> patent • In vitro tests planned for in silico selected compounds on 2 targets docked in the winter of 2006 • New target ready to be deployed both on EGEE and Africa@home • Diabetes • Large scale docking started 2 days ago on amylase (CNU, KISTI, LPC) • AIDS • Collaboration between Univ. Cyprus and ITB-CNR V. Breton , FCPPL, 150108

  19. Credits • Development of the WISDOM environment • ASGC: Yu-Hsuan Chen, Li-Yung Ho, Hurng-Chun Lee • ITB-CNR: G. Trombetti • CNRS-IN2P3: V. Bloch, M. Diarena, J. Salzemann • HealthGrid: B. Grenier, N. Spalinger, N. Verhaeghe • Biochemical preparation and analysis • ASGC: Y-T Wu • Chonnam National University: D. Kim & al • CNRS-IN2P3: A. Da Costa, V. Kasam • ITB-CNR: L. Milanesi & al • Projects supporting WISDOM • Projects providing human resources: BioinfoGRID, EGEE, Embrace • Projects providing computing resources: AuverGRID, EELA, EGEE, EUMedGRID, EUChinaGRID, TWGrid V. Breton , FCPPL, 150108

More Related